Shopping Cart 0
Cart Subtotal
AED 0

Regeneron Pharmaceuticals Inc (REGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Regeneron Pharmaceuticals Inc (Regeneron) is a biopharmaceutical company, which discovers, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The company's six US FDA-approved medicines and product candidates in development help patients with eye diseases, asthma, pain, cancer and heart, allergic, inflammatory and infectious diseases. It develops products based on its VelociSuite technology platforms, which include VelociGene, VelocImmune, VelociMouse, VelociMab and other related technologies. Regeneron also has various product candidates under clinical development for treating asthma, pain, cancer, atopic dermatitis and infectious diseases. It has subsidiaries in Belgium, Spain, Ireland, the Netherlands, the US and the UK. Regeneron is headquartered in Tarrytown, New York, the US.

Regeneron Pharmaceuticals Inc (REGN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 6

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Regeneron Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 12

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 16

Asset Purchase 16

Regeneron Pharma Acquires Rights To Two Antibodies From Sanofi 16

Venture Financing 17

Decibel Therapeutics Raises USD55 Million in Series C Venture Financing 17

Private Equity 19

TRC Capital To Acquire 1.06% Stake In Regeneron Pharma For USD 161 Million 19

Partnerships 20

Regeneron Pharma and bluebird bio to Enter into Collaboration Agreement 20

Replimune Enters into Co-Development Agreement with Regeneron Pharma 22

Regeneron Pharma Enters into Agreement with Alnylam Pharma 23

Regeneron Pharma and ISA Pharma Enter into Partnership 24

Regeneron Pharma Enters into Co-Development Agreement with Decibel Therapeutics 25

Aimmune Therapeutics Enters into Agreement with Regeneron Ireland and Sanofi Biotech 26

Regeneron Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority for Infectious Diseases 27

Regeneron Pharma and SillaJen Biotherapeutics Enter into Agreement 28

Inovio Pharma and Regeneron Pharma Enter into Agreement 29

Indivumed Enters into Agreement with Regeneron Pharma 30

Regeneron Pharma Enters into Co-Development Agreement with Ocular Therapeutix 31

Regeneron Pharma Enters into Co-Development Agreement with Teva Pharma for Fasinumab 33

Regeneron Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority 34

Bayer Enters into Co-Development Agreement with Regeneron Pharma 35

Regeneron Pharma Enters into Agreement with Mitsubishi Tanabe Pharma 36

Regeneron Pharma Enters into Research Agreement with Icahn School of Medicine at Mount Sinai 37

Regeneron Pharma Enters into Development Agreement with BARDA 38

Regeneron Pharma Amends Co-Development Agreement with Sanofi 39

Regeneron Pharma Amends Co-Development Agreement with Sanofi 41

Regeneron Pharma Enters Into Co-Development Agreement With Avalanche Biotech For Gene Therapy Products 42

Regeneron And Bayer Enter Into Co-Development Agreement For Eylea Combination Treatment 43

Regeneron Pharma And Bayer Yakuhin Enter Into Co-Promotion Agreement With Santen Pharma For Eylea 44

Licensing Agreements 46

Kiniksa Pharma Enters into Licensing Agreement with Regeneron 46

Neovii Pharmaceuticals Enters into Licenses Agreement with Regeneron 47

Regeneron Pharma Enters into Licensing Agreement with Intellia Therapeutics 48

Regeneron Pharma Enters into Licensing Agreement with MedImmune 50

Regeneron Pharma Enters into Licensing Agreement with Adicet Bio 51

Regeneron Pharma Enters into Licensing Agreement with ERS Genomics 52

Regeneron Pharmaceuticals Inc-Key Competitors 53

Regeneron Pharmaceuticals Inc-Key Employees 54

Regeneron Pharmaceuticals Inc-Locations And Subsidiaries 56

Head Office 56

Other Locations & Subsidiaries 56

Recent Developments 57

Financial Announcements 57

Nov 06, 2018: Regeneron reports third quarter 2018 financial and operating results 57

Aug 02, 2018: Regeneron reports second quarter 2018 financial and operating results 59

May 03, 2018: Regeneron Reports First Quarter 2018 Financial And Operating Results 62

Feb 08, 2018: Regeneron Reports Fourth Quarter and Full Year 2017 Financial Results 65

Nov 08, 2017: Regeneron Reports Third Quarter 2017 Financial and Operating Results 68

Aug 03, 2017: Regeneron Reports Second Quarter 2017 Financial and Operating Results 71

May 04, 2017: Regeneron Reports First Quarter 2017 Financial And Operating Results 74

Feb 09, 2017: Regeneron Reports Fourth Quarter And Full Year 2016 Financial And Operating Results 77

Corporate Communications 81

Jun 23, 2018: Regeneron Announces Departure of Michael Aberman, M.D., Senior Vice President of Strategy and Investor Relations 81

Feb 12, 2018: Regeneron Announces Appointment of Marion McCourt as Senior Vice President and Head of Commercial 82

Jan 31, 2017: Tony Coles, M.D., Elected To Regeneron Board Of Directors 83

Legal and Regulatory 84

Mar 19, 2018: Regeneron Pharmaceuticals Announce Regarding Novartis Complaint on '688 Patent 84

Dec 27, 2017: Merus Announces the U.S. Court of Appeals for the Federal Circuit Denies Regeneron's Petition to Rehear the Panel's Decision Affirming Merus' Inequitable Conduct Claim Against Regeneron 85

Jul 28, 2017: U.S. Court of Appeals for the Federal Circuit Affirms Merus' Inequitable Conduct Claim Against Regeneron 86

Government and Public Interest 87

Aug 07, 2018: Regeneron: Statement regarding new CMS guidance for part B drugs 87

Mar 21, 2018: Regeneron Genetics Center Publication in New England Journal of Medicine Identifies New Genetic Variant Providing Protection from Chronic Liver Disease 88

Mar 13, 2018: Teen Scientists Win USD 1.8 Million at Regeneron Science Talent Search 2018 with Top Awards for Novel Research on Crop Blight, Vaping and Rare Disease 90

Mar 22, 2017: U.K. Biobank, Regeneron and GSK Announce Largest Gene Sequencing Initiative on World's Most Detailed Health Database to Improve Drug Discovery and Disease Diagnosis 92

Product News 94

10/03/2018: Onco360 selected as the exclusive specialty pharmacy for libtayo (cemiplimab-rwlc) limited distribution pharmacy network 94

09/28/2018: FDA approves Libtayo (cemiplimab-rwlc) as first and only treatment for advanced cutaneous squamous cell carcinoma 95

09/08/2017: Sanofi and Regeneron Announce That Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma 97

08/23/2018: Intellia Therapeutics presents progress in lead in vivo program at cold spring harbor laboratory's fourth meeting on genome engineering: the CRISPR-Cas revolution 98

08/17/2017: Notice of the Start of a Japanese Phase 2/3 Clinical Study of the Anti-NGF Antibody MT-5547 in Osteoarthritis 99

05/31/2018: Regeneron's Investigational Ebola Treatment Shipping to Democratic Republic of the Congo for Use in Current Outbreak 100

04/25/2017: Regeneron And Sanofi Announce FDA Approval Of A New Once-Monthly Dosing Option For Praluent (Alirocumab) Injection 101

02/08/2017: Appeals Court Grants Stay of Permanent Injunction for Praluent (alirocumab) During Appeals Process 102

01/13/2017: Sanofi and Regeneron File Notice of Appeal and Motion to Stay (Suspend) Injunction with Federal Circuit Court of Appeals in Patent Case Regarding Praluent (alirocumab) Injection 103

Product Approvals 104

Apr 30, 2018: FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma 104

Apr 03, 2018: EMA to Review Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma 105

Clinical Trials 106

Oct 08, 2018: Libtayo (Cemiplimab-RWLC) data at ESMO 2018 congress provide new insights in six tumor types under investigation 106

Aug 17, 2018: Fasinumab Phase III osteoarthritis trial meets endpoints 108

Jun 04, 2018: New England Journal of Medicine Publishes pivotal Cemiplimab Trials Showing Positive Results in Advanced Cutaneous Squamous Cell Carcinoma 109

May 16, 2018: Regeneron and Sanofi Share First Positive Clinical Data for Cemiplimab in Advanced Non-small Cell Lung Cancer at ASCO 111

Feb 27, 2018: Intellia Therapeutics Announces Publication in Cell Reports of Preclinical Data Demonstrating Effective CRISPR/Cas9 Genome Editing Using Lipid Nanoparticle (LNP) Delivery Technology 112

Dec 13, 2017: Sanofi and Regeneron announce positive topline pivotal results for PD-1 antibody cemiplimab in advanced cutaneous squamous cell carcinoma 113

Nov 27, 2017: Regeneron Provides Update on Eylea (Aflibercept) Injection and Nesvacumab (Ang2 Antibody) Combination Program 114

Nov 07, 2017: Regeneron and Sanofi to Present New Analyses from the Praluent (alirocumab) Injection ODYSSEY Clinical Trial Program at the AHA Scientific Sessions 2017 115

Nov 01, 2017: Regeneron to Share Clinical Progress of Cemiplimab (REGN2810) in B-Cell Lymphomas at the 2017 ASH Annual Meeting 117

Nov 01, 2017: Regeneron to Share Clinical Progress of REGN1979 in B-Cell Lymphomas at the 2017 ASH Annual Meeting 118

Aug 25, 2017: Regeneron and Sanofi to Present New Analyses from Praluent Injection Trials at the ESC Congress 2017 119

Jun 11, 2017: Medication That Inhibits PCSK9 Safely Reduces Cardiovascular Risk in Patients with Type 2 Diabetes 121

Jun 11, 2017: Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent (alirocumab) in Individuals with Diabetes and Hypercholesterolemia 123

Jun 04, 2017: Regeneron And Sanofi Present Positive Study Results For Investigational PD-1 Antibody REGN2810 At American Society Of Clinical Oncology (Asco) Annual Meeting 125

Mar 07, 2017: Regeneron and Sanofi to Present New Phase 3 Praluent (alirocumab) Injection Clinical Trial Analyses at ACC.17 Scientific Sessions 126

Other Significant Developments 128

Sep 11, 2018: Governor Cuomo announces Regeneron to create 1,500 biotech jobs in major New York expansion 128

Aug 09, 2018: Ebola virus experts discover powerful, new approach for future therapeutics 130

May 18, 2018: Experimental MERS Treatments Enter Clinical Trial 131

Appendix 132

Methodology 132

About GlobalData 132

Contact Us 132

Disclaimer 132


List Of Figure

List of Figures

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Regeneron Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Regeneron Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 11

Regeneron Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 12

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Regeneron Pharma Acquires Rights To Two Antibodies From Sanofi 16

Decibel Therapeutics Raises USD55 Million in Series C Venture Financing 17

TRC Capital To Acquire 1.06% Stake In Regeneron Pharma For USD 161 Million 19

Regeneron Pharma and bluebird bio to Enter into Collaboration Agreement 20

Replimune Enters into Co-Development Agreement with Regeneron Pharma 22

Regeneron Pharma Enters into Agreement with Alnylam Pharma 23

Regeneron Pharma and ISA Pharma Enter into Partnership 24

Regeneron Pharma Enters into Co-Development Agreement with Decibel Therapeutics 25

Aimmune Therapeutics Enters into Agreement with Regeneron Ireland and Sanofi Biotech 26

Regeneron Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority for Infectious Diseases 27

Regeneron Pharma and SillaJen Biotherapeutics Enter into Agreement 28

Inovio Pharma and Regeneron Pharma Enter into Agreement 29

Indivumed Enters into Agreement with Regeneron Pharma 30

Regeneron Pharma Enters into Co-Development Agreement with Ocular Therapeutix 31

Regeneron Pharma Enters into Co-Development Agreement with Teva Pharma for Fasinumab 33

Regeneron Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority 34

Bayer Enters into Co-Development Agreement with Regeneron Pharma 35

Regeneron Pharma Enters into Agreement with Mitsubishi Tanabe Pharma 36

Regeneron Pharma Enters into Research Agreement with Icahn School of Medicine at Mount Sinai 37

Regeneron Pharma Enters into Development Agreement with BARDA 38

Regeneron Pharma Amends Co-Development Agreement with Sanofi 39

Regeneron Pharma Amends Co-Development Agreement with Sanofi 41

Regeneron Pharma Enters Into Co-Development Agreement With Avalanche Biotech For Gene Therapy Products 42

Regeneron And Bayer Enter Into Co-Development Agreement For Eylea Combination Treatment 43

Regeneron Pharma And Bayer Yakuhin Enter Into Co-Promotion Agreement With Santen Pharma For Eylea 44

Kiniksa Pharma Enters into Licensing Agreement with Regeneron 46

Neovii Pharmaceuticals Enters into Licenses Agreement with Regeneron 47

Regeneron Pharma Enters into Licensing Agreement with Intellia Therapeutics 48

Regeneron Pharma Enters into Licensing Agreement with MedImmune 50

Regeneron Pharma Enters into Licensing Agreement with Adicet Bio 51

Regeneron Pharma Enters into Licensing Agreement with ERS Genomics 52

Regeneron Pharmaceuticals Inc, Key Competitors 53

Regeneron Pharmaceuticals Inc, Key Employees 54

Regeneron Pharmaceuticals Inc, Other Locations 56

Regeneron Pharmaceuticals Inc, Subsidiaries 56

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Regeneron Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Regeneron Pharmaceuticals Inc (Regeneron) is a biopharmaceutical company, which discovers, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The company's six US FDA-approved medicines and product candidates in development help patients with eye diseases, asthma, pain, cancer and heart, allergic, inflammatory and infectious diseases. It develops products based on its VelociSuite technology platforms, which include VelociGene, VelocImmune, VelociMouse, VelociMab and other related technologies. Regeneron also has various product candidates under clinical development for treating asthma, pain, cancer, atopic dermatitis and infectious diseases. It has subsidiaries in Belgium, Spain, Ireland, the Netherlands, the US and the UK. Regeneron is headquartered in Tarrytown, New York, the US.

Regeneron Pharmaceuticals Inc (REGN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 6

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Regeneron Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 12

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 16

Asset Purchase 16

Regeneron Pharma Acquires Rights To Two Antibodies From Sanofi 16

Venture Financing 17

Decibel Therapeutics Raises USD55 Million in Series C Venture Financing 17

Private Equity 19

TRC Capital To Acquire 1.06% Stake In Regeneron Pharma For USD 161 Million 19

Partnerships 20

Regeneron Pharma and bluebird bio to Enter into Collaboration Agreement 20

Replimune Enters into Co-Development Agreement with Regeneron Pharma 22

Regeneron Pharma Enters into Agreement with Alnylam Pharma 23

Regeneron Pharma and ISA Pharma Enter into Partnership 24

Regeneron Pharma Enters into Co-Development Agreement with Decibel Therapeutics 25

Aimmune Therapeutics Enters into Agreement with Regeneron Ireland and Sanofi Biotech 26

Regeneron Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority for Infectious Diseases 27

Regeneron Pharma and SillaJen Biotherapeutics Enter into Agreement 28

Inovio Pharma and Regeneron Pharma Enter into Agreement 29

Indivumed Enters into Agreement with Regeneron Pharma 30

Regeneron Pharma Enters into Co-Development Agreement with Ocular Therapeutix 31

Regeneron Pharma Enters into Co-Development Agreement with Teva Pharma for Fasinumab 33

Regeneron Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority 34

Bayer Enters into Co-Development Agreement with Regeneron Pharma 35

Regeneron Pharma Enters into Agreement with Mitsubishi Tanabe Pharma 36

Regeneron Pharma Enters into Research Agreement with Icahn School of Medicine at Mount Sinai 37

Regeneron Pharma Enters into Development Agreement with BARDA 38

Regeneron Pharma Amends Co-Development Agreement with Sanofi 39

Regeneron Pharma Amends Co-Development Agreement with Sanofi 41

Regeneron Pharma Enters Into Co-Development Agreement With Avalanche Biotech For Gene Therapy Products 42

Regeneron And Bayer Enter Into Co-Development Agreement For Eylea Combination Treatment 43

Regeneron Pharma And Bayer Yakuhin Enter Into Co-Promotion Agreement With Santen Pharma For Eylea 44

Licensing Agreements 46

Kiniksa Pharma Enters into Licensing Agreement with Regeneron 46

Neovii Pharmaceuticals Enters into Licenses Agreement with Regeneron 47

Regeneron Pharma Enters into Licensing Agreement with Intellia Therapeutics 48

Regeneron Pharma Enters into Licensing Agreement with MedImmune 50

Regeneron Pharma Enters into Licensing Agreement with Adicet Bio 51

Regeneron Pharma Enters into Licensing Agreement with ERS Genomics 52

Regeneron Pharmaceuticals Inc-Key Competitors 53

Regeneron Pharmaceuticals Inc-Key Employees 54

Regeneron Pharmaceuticals Inc-Locations And Subsidiaries 56

Head Office 56

Other Locations & Subsidiaries 56

Recent Developments 57

Financial Announcements 57

Nov 06, 2018: Regeneron reports third quarter 2018 financial and operating results 57

Aug 02, 2018: Regeneron reports second quarter 2018 financial and operating results 59

May 03, 2018: Regeneron Reports First Quarter 2018 Financial And Operating Results 62

Feb 08, 2018: Regeneron Reports Fourth Quarter and Full Year 2017 Financial Results 65

Nov 08, 2017: Regeneron Reports Third Quarter 2017 Financial and Operating Results 68

Aug 03, 2017: Regeneron Reports Second Quarter 2017 Financial and Operating Results 71

May 04, 2017: Regeneron Reports First Quarter 2017 Financial And Operating Results 74

Feb 09, 2017: Regeneron Reports Fourth Quarter And Full Year 2016 Financial And Operating Results 77

Corporate Communications 81

Jun 23, 2018: Regeneron Announces Departure of Michael Aberman, M.D., Senior Vice President of Strategy and Investor Relations 81

Feb 12, 2018: Regeneron Announces Appointment of Marion McCourt as Senior Vice President and Head of Commercial 82

Jan 31, 2017: Tony Coles, M.D., Elected To Regeneron Board Of Directors 83

Legal and Regulatory 84

Mar 19, 2018: Regeneron Pharmaceuticals Announce Regarding Novartis Complaint on '688 Patent 84

Dec 27, 2017: Merus Announces the U.S. Court of Appeals for the Federal Circuit Denies Regeneron's Petition to Rehear the Panel's Decision Affirming Merus' Inequitable Conduct Claim Against Regeneron 85

Jul 28, 2017: U.S. Court of Appeals for the Federal Circuit Affirms Merus' Inequitable Conduct Claim Against Regeneron 86

Government and Public Interest 87

Aug 07, 2018: Regeneron: Statement regarding new CMS guidance for part B drugs 87

Mar 21, 2018: Regeneron Genetics Center Publication in New England Journal of Medicine Identifies New Genetic Variant Providing Protection from Chronic Liver Disease 88

Mar 13, 2018: Teen Scientists Win USD 1.8 Million at Regeneron Science Talent Search 2018 with Top Awards for Novel Research on Crop Blight, Vaping and Rare Disease 90

Mar 22, 2017: U.K. Biobank, Regeneron and GSK Announce Largest Gene Sequencing Initiative on World's Most Detailed Health Database to Improve Drug Discovery and Disease Diagnosis 92

Product News 94

10/03/2018: Onco360 selected as the exclusive specialty pharmacy for libtayo (cemiplimab-rwlc) limited distribution pharmacy network 94

09/28/2018: FDA approves Libtayo (cemiplimab-rwlc) as first and only treatment for advanced cutaneous squamous cell carcinoma 95

09/08/2017: Sanofi and Regeneron Announce That Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma 97

08/23/2018: Intellia Therapeutics presents progress in lead in vivo program at cold spring harbor laboratory's fourth meeting on genome engineering: the CRISPR-Cas revolution 98

08/17/2017: Notice of the Start of a Japanese Phase 2/3 Clinical Study of the Anti-NGF Antibody MT-5547 in Osteoarthritis 99

05/31/2018: Regeneron's Investigational Ebola Treatment Shipping to Democratic Republic of the Congo for Use in Current Outbreak 100

04/25/2017: Regeneron And Sanofi Announce FDA Approval Of A New Once-Monthly Dosing Option For Praluent (Alirocumab) Injection 101

02/08/2017: Appeals Court Grants Stay of Permanent Injunction for Praluent (alirocumab) During Appeals Process 102

01/13/2017: Sanofi and Regeneron File Notice of Appeal and Motion to Stay (Suspend) Injunction with Federal Circuit Court of Appeals in Patent Case Regarding Praluent (alirocumab) Injection 103

Product Approvals 104

Apr 30, 2018: FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma 104

Apr 03, 2018: EMA to Review Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma 105

Clinical Trials 106

Oct 08, 2018: Libtayo (Cemiplimab-RWLC) data at ESMO 2018 congress provide new insights in six tumor types under investigation 106

Aug 17, 2018: Fasinumab Phase III osteoarthritis trial meets endpoints 108

Jun 04, 2018: New England Journal of Medicine Publishes pivotal Cemiplimab Trials Showing Positive Results in Advanced Cutaneous Squamous Cell Carcinoma 109

May 16, 2018: Regeneron and Sanofi Share First Positive Clinical Data for Cemiplimab in Advanced Non-small Cell Lung Cancer at ASCO 111

Feb 27, 2018: Intellia Therapeutics Announces Publication in Cell Reports of Preclinical Data Demonstrating Effective CRISPR/Cas9 Genome Editing Using Lipid Nanoparticle (LNP) Delivery Technology 112

Dec 13, 2017: Sanofi and Regeneron announce positive topline pivotal results for PD-1 antibody cemiplimab in advanced cutaneous squamous cell carcinoma 113

Nov 27, 2017: Regeneron Provides Update on Eylea (Aflibercept) Injection and Nesvacumab (Ang2 Antibody) Combination Program 114

Nov 07, 2017: Regeneron and Sanofi to Present New Analyses from the Praluent (alirocumab) Injection ODYSSEY Clinical Trial Program at the AHA Scientific Sessions 2017 115

Nov 01, 2017: Regeneron to Share Clinical Progress of Cemiplimab (REGN2810) in B-Cell Lymphomas at the 2017 ASH Annual Meeting 117

Nov 01, 2017: Regeneron to Share Clinical Progress of REGN1979 in B-Cell Lymphomas at the 2017 ASH Annual Meeting 118

Aug 25, 2017: Regeneron and Sanofi to Present New Analyses from Praluent Injection Trials at the ESC Congress 2017 119

Jun 11, 2017: Medication That Inhibits PCSK9 Safely Reduces Cardiovascular Risk in Patients with Type 2 Diabetes 121

Jun 11, 2017: Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent (alirocumab) in Individuals with Diabetes and Hypercholesterolemia 123

Jun 04, 2017: Regeneron And Sanofi Present Positive Study Results For Investigational PD-1 Antibody REGN2810 At American Society Of Clinical Oncology (Asco) Annual Meeting 125

Mar 07, 2017: Regeneron and Sanofi to Present New Phase 3 Praluent (alirocumab) Injection Clinical Trial Analyses at ACC.17 Scientific Sessions 126

Other Significant Developments 128

Sep 11, 2018: Governor Cuomo announces Regeneron to create 1,500 biotech jobs in major New York expansion 128

Aug 09, 2018: Ebola virus experts discover powerful, new approach for future therapeutics 130

May 18, 2018: Experimental MERS Treatments Enter Clinical Trial 131

Appendix 132

Methodology 132

About GlobalData 132

Contact Us 132

Disclaimer 132


List Of Figure

List of Figures

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Regeneron Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Regeneron Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 11

Regeneron Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 12

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Regeneron Pharma Acquires Rights To Two Antibodies From Sanofi 16

Decibel Therapeutics Raises USD55 Million in Series C Venture Financing 17

TRC Capital To Acquire 1.06% Stake In Regeneron Pharma For USD 161 Million 19

Regeneron Pharma and bluebird bio to Enter into Collaboration Agreement 20

Replimune Enters into Co-Development Agreement with Regeneron Pharma 22

Regeneron Pharma Enters into Agreement with Alnylam Pharma 23

Regeneron Pharma and ISA Pharma Enter into Partnership 24

Regeneron Pharma Enters into Co-Development Agreement with Decibel Therapeutics 25

Aimmune Therapeutics Enters into Agreement with Regeneron Ireland and Sanofi Biotech 26

Regeneron Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority for Infectious Diseases 27

Regeneron Pharma and SillaJen Biotherapeutics Enter into Agreement 28

Inovio Pharma and Regeneron Pharma Enter into Agreement 29

Indivumed Enters into Agreement with Regeneron Pharma 30

Regeneron Pharma Enters into Co-Development Agreement with Ocular Therapeutix 31

Regeneron Pharma Enters into Co-Development Agreement with Teva Pharma for Fasinumab 33

Regeneron Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority 34

Bayer Enters into Co-Development Agreement with Regeneron Pharma 35

Regeneron Pharma Enters into Agreement with Mitsubishi Tanabe Pharma 36

Regeneron Pharma Enters into Research Agreement with Icahn School of Medicine at Mount Sinai 37

Regeneron Pharma Enters into Development Agreement with BARDA 38

Regeneron Pharma Amends Co-Development Agreement with Sanofi 39

Regeneron Pharma Amends Co-Development Agreement with Sanofi 41

Regeneron Pharma Enters Into Co-Development Agreement With Avalanche Biotech For Gene Therapy Products 42

Regeneron And Bayer Enter Into Co-Development Agreement For Eylea Combination Treatment 43

Regeneron Pharma And Bayer Yakuhin Enter Into Co-Promotion Agreement With Santen Pharma For Eylea 44

Kiniksa Pharma Enters into Licensing Agreement with Regeneron 46

Neovii Pharmaceuticals Enters into Licenses Agreement with Regeneron 47

Regeneron Pharma Enters into Licensing Agreement with Intellia Therapeutics 48

Regeneron Pharma Enters into Licensing Agreement with MedImmune 50

Regeneron Pharma Enters into Licensing Agreement with Adicet Bio 51

Regeneron Pharma Enters into Licensing Agreement with ERS Genomics 52

Regeneron Pharmaceuticals Inc, Key Competitors 53

Regeneron Pharmaceuticals Inc, Key Employees 54

Regeneron Pharmaceuticals Inc, Other Locations 56

Regeneron Pharmaceuticals Inc, Subsidiaries 56

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Regeneron Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.